Mitochondrial targeted astaxanthin liposomes for myocardial ischemia-reperfusion injury based on oxidative stress. (August 2022)

• Record Type: Journal Article
• Authors: Gao, Feng; Zhao, Yongcheng; Zhang, Bin; Xiao, Chunwei; Sun, Zhanfa; Gao, Yuan; Dou, Xueyong
• Is Part Of: Journal of biomaterials applications. Volume 37:Number 2(2022)
• Page Start: 303
• Page End: 314
• Publication Date: 2022-08
• Subjects: myocardial ischemia-reperfusion injury -- mitochondrial targeted -- astaxanthin -- liposomes -- oxidative stress; Biomedical engineering -- Periodicals; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1177/08853282221087102
• Languages: English
• ISSNs: 0885-3282

Abstract

Myocardial ischemia-reperfusion injury (MI/RI) refers to the clinical state of decreased coronary blood flow caused by various causes. The main pathogenesis of MI/RI is mitochondrial oxidative damage. In this study, we designed a novel mitochondrial targeted astaxanthin (AST) liposome, namely, STPP-AST-LIP, targeting mitochondria of H9c2 myocardial cells. STPP-AST-LIP not only reduced the production of mitochondrial reactive oxygen species (ROS), but also increased the survival rate of MI/RI H9c2 cells. In addition, rat experiments further confirmed that STPP-AST-LIP could improve myocardial cardiac function in MI/RI rats, significantly inhibited apoptosis of myocardial cells, and had a protective effect on the heart of rats after MI/RI.